[Asia Economy Reporter Moon Hyewon] JinMatrix announced on the 8th that it has obtained a US patent for its proprietary multiplex molecular diagnostic core technology, ‘C-Tag’.


The patented technology is a platform used in the Neoplex multiplex molecular diagnostic product line. The company explained that it is recognized as a next-generation core technology capable of advanced multiplexing, surpassing the previously known limit of up to five simultaneous analyses in conventional real-time PCR technology.


Hot Picks Today

"What If It's Already Selling This Well?" Sales Soar 18-Fold... Flying Off Shelves at Convenience Stores [How We Shop Today] "What If It's Already Selling This Well?" Sales Soar 18-Fold... Flying Off Shelves at Convenience Stores [How We Shop Today]

JinMatrix is currently preparing a comprehensive respiratory virus panel rapid diagnostic product applying the C-Tag core technology to its COVID-19 diagnostic products, which are being exported to Europe, the Middle East, and other regions.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing